Iovance Biotherapeutics Inc (IOVA) Company Profile & Statistics

Iovance Biotherapeutics Inc
IOVA
(Nasdaq - US)
Closed
8.24
+0.10 (+1.23%)
in:usd•As of: Nov 21, 2024 15:59 UTC -5
After Market:8.19-0.05 (-0.61%)
Open
8.13
High
8.38
Low
7.99

About Iovance Biotherapeutics Inc

CEO

Frederick G. Vogt

Headquarters

825 industrial road, suite 400

san carlos, ca 94070, united states

Auditor

Ernst & Young LLP

Employees

557

Share Holders

Website

www.iovance.com

Industry

biotechnology

Sector

health technology

Company Overview

Iovance Biotherapeutics is a clinical-stage pharmaceutical company primarily focused on the development and commercialization of novel T cell-based cancer immunotherapies. These immunotherapies use Generation 2 ('Gen 2') tumor infiltrating lymphocyte (TIL), which harnesses the power of a patient's own immune system to eradicate cancer cells.

Iovance Biotherapeutics Inc Statistics

Valuation Measures

Market Capitalization ²	2.51B
Enterprise Value	2.35B
Enterprise Value/EBITDA (ttm)	-5.91
Price to Earnings Ratio (ttm)	N/A
Price to Book (mrq)	2.96
Price to Sales (ttm)	27.47
Price to Cash (ytd)	N/A

Profitability

Gross Margin (ttm)	-422.49%
Operating Margin (ttm)	-451.25%
Profit Margin (ttm)	-10100.17%
Return on Equity (ttm)	-58.43%
Return on Invested Capital (ttm)	-59.87%
Return on Assets (ttm)	-45.48%

Income Statement

Revenue (ttm)	90.86M
Revenue Per Share (ttm)	0.30
Gross Profit (ttm)	8.04M
EBITDA (ttm)³	-397.54M
Net Income Avi to Common (ttm)	-410.00M
Diluted EPS (ttm)	-1.49

Share Statistics

Beta (5Y Monthly)	0.60
52-Week Change	50.09%
S&P500 52-Week Change	30.55%
S&P500 Member	No
Stock Optionable	Yes
Total Shares Outstanding ¹	304.78M
Dividend Yield	0.00%
Float ⁴	267.90M
% Held by Insiders	12.10%
% Held by Institutions	77.03%

Balance Sheet

Total Cash (mrq)	397.49M
Total Cash Per Share (mrq)	1.30
Total Debt (mrq)	1000.00K
Total Debt/Equity (mrq)	0.13%
Current Ratio (mrq)	4.22%
Quick Ratio (mrq)	3.90%
Book Value Per Share (mrq)	2.54

Cash Flow

Operating Cash Flow Per Share (ytd)	-0.92
Free Cash Flow (ytd)	-286.58M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. Stock price provided by Xignite. All numbers are rounded to the closest decimal.

¹ Total Shares outstanding is taken from the most recently filed quarterly or annual report.

² Market Cap is calculated using total shares outstanding and the most recent share price.

³ EBITDA is calculated using methodology that may differ from that used by a company in its reporting.

⁴ The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.

Iovance Biotherapeutics Inc

Trade With A Regulated Broker